Development of an effective
vaccine against
leishmaniasis is possible due to the fact that individuals cured from
cutaneous leishmaniasis (CL) are protected from further
infection. First generation
Leishmania vaccines consisting of whole killed parasites reached to phase 3 clinical trials but failed to show enough efficacies mainly due to the lack of an appropriate adjuvant. In this study, an efficient liposomal
protein-based
vaccine against Leishmania major
infection was developed using soluble Leishmania
antigens (SLA) as a first generation
vaccine and
cytidine phosphate guanosine oligodeoxynucleotides (CpG ODNs) as an immunostimulatory adjuvant. 1, 2-Dioleoyl-3-trimethylammonium-propane was used as a cationic
lipid to prepare the
liposomes due to its intrinsic adjuvanticity. BALB/c mice were immunized subcutaneously (SC), three times in 2-week intervals, with Lip-SLA-CpG, Lip-SLA, SLA + CpG, SLA, or
HEPES buffer. As criteria for protection, footpad swelling at the site of challenge and spleen parasite loads were assessed, and the immune responses were evaluated by determination of IFN-γ and
IL-4 levels of cultured splenocytes, and
IgG subtypes. The group of mice that received Lip-SLA-CpG showed a significantly smaller footpad swelling, lower spleen parasite burden, higher
IgG2a antibody, and lower
IL-4 level compared to the control groups. It is concluded that cationic
liposomes containing SLA and CpG ODNs are appropriate to induce Th1 type of immune response and protection against
leishmaniasis.